KRAS and neoplasm: The development of these mutations following anti-EGFR targeted treatment, can be a consequence of alterations rising from pre-existent KRAS altered clones, or due to new mutations derived from stress conditions induced by targeted therapy to the tumor and tumor microenvironment.